Drug Trial Radar · NCT06575153
Phase 1 Study of ART5803 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Sep 19, 2024
Primary completion
Sep 11, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Arialys TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and immunogenicity of ART5803 compared with placebo in healthy adult participants
Conditions
- Autoimmune Encephalitis
Interventions
ART5803Drug
A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety will be assessed by the incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: 12 weeks
- Safety will be assessed by clinically significant changes in physical and neurological examination findingsTime frame: 12 weeks
- Safety by assessed by clinically significant changes in vital signsTime frame: 12 weeks
- Safety by assessed by clinically significant changes in clinical laboratory outcomesTime frame: 12 weeks
- Safety by assessed by clinically significant changes in 12-lead ECG findingsTime frame: 12 weeks
- Safety by assessed by clinically significant changes in concomitant medicationsTime frame: 12 weeks
- Safety by assessed by clinically significant changes in presence of anti-drug antibodies (ADAs)Time frame: 12 weeks
- Safety will be assessed by incidence of dose-limiting toxicity (DLTs)Time frame: 12 weeks
- Safety will be assessed by change in suicidal tendency measured by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.